WHO and Partners Launch Global Roadmap to Address Hypertension in Pregnancy

October 8, 2026 • PressClubAi • 1 month ago • 2 min read

The World Health Organization (WHO) and partner organizations launched a new global roadmap at the Society for Maternal-Fetal Medicine Global Conference to address hypertensive disorders of pregnancy, including pre-eclampsia. The strategic framework, titled the Global roadmap for hypertensive disorders of pregnancy from 2026 to 2035 and beyond, aims to reduce maternal and newborn mortality linked to these conditions.

According to the WHO, hypertensive disorders complicate an estimated 10% to 15% of pregnancies worldwide and contribute to approximately 16% of global maternal deaths. The agency estimates these conditions cause roughly 42,000 maternal deaths and over 500,000 stillbirths and newborn deaths each year.

The initiative outlines coordinated measures across several areas, including research and innovation, global clinical guidance, diagnostic and medicine access, implementation, advocacy, and accountability.

The roadmap notes that in many nations, pregnant women lack consistent access to fundamental healthcare tools such as blood-pressure monitoring, urine protein testing, and essential treatments like aspirin, antihypertensives, and magnesium sulfate. Factors such as weak referral systems, healthcare worker shortages, and restricted emergency obstetric services also contribute to delays in critical care.

“Pre-eclampsia can develop in any pregnancy. Whether it becomes fatal depends on whether a woman's blood pressure was checked in time, and whether quality emergency care was within reach when it turned severe,” said Dr Pascale Allotey, Director of WHO’s Department of Sexual, Reproductive, Maternal, Child, Adolescent Health and Ageing.

The WHO highlighted an ongoing innovation gap, reporting that research investments have largely targeted diagnostics rather than the development of regulator-approved medicines specifically designed to prevent or treat pre-eclampsia and eclampsia. In response, the organization convened over 140 partners at a May 2026 summit to establish 20 priority research questions aimed at guiding future clinical and preventive investments.

The health agency also emphasized the long-term health risks of pre-eclampsia, noting that affected women face higher risks of chronic hypertension, cardiovascular disease, stroke, and kidney disease later in life. Additionally, children exposed to hypertensive disorders during pregnancy may encounter heightened risks tied to preterm birth as well as long-term metabolic and cardiovascular issues.

The WHO is calling on governments, researchers, industry, and civil society partners to coordinate funding and healthcare delivery to expand access to interventions for affected women and newborns.

Source

Based on material from Read source material

World Health Organization (WHO)

United Nations source who.int

Official global public health agency material; technical guidance reflects WHO assessments.

How PressClub produces articles

PressClub uses AI to write news from collected source material, with formatted source text as a fallback. The linked material provides the source’s account; this article does not establish independent verification. Read the source for its own wording and updates.

Keep Going

Read next

Catch up with a briefing, browse more stories, or share this article.

Briefing Read the latest briefing Catch the bigger picture in one recap. Coverage Explore coverage Find topics receiving more reports than usual.
Continue reading

More news to read

Browse more published news. The topic labels show what each article covers.

Browse this topic